PT  - JOURNAL ARTICLE
AU  - Matthew D. Galbraith
AU  - Kohl T. Kinning
AU  - Kelly D. Sullivan
AU  - Paula Araya
AU  - Keith P. Smith
AU  - Ross E. Granrath
AU  - Jessica R. Shaw
AU  - Ryan Baxter
AU  - Kimberly R. Jordan
AU  - Seth Russell
AU  - Monika Dzieciatkowska
AU  - Julie A. Reisz
AU  - Fabia Gamboni
AU  - Francesca Cendali
AU  - Tusharkanti Ghosh
AU  - Andrew A. Monte
AU  - Tellen D. Bennett
AU  - Kirk C. Hansen
AU  - Elena W.Y. Hsieh
AU  - Angelo D’Alessandro
AU  - Joaquin M. Espinosa
TI  - Specialized interferon ligand action in COVID19
AID  - 10.1101/2021.07.29.21261325
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.29.21261325
4099  - http://medrxiv.org/content/early/2021/08/01/2021.07.29.21261325.short
4100  - http://medrxiv.org/content/early/2021/08/01/2021.07.29.21261325.full
AB  - The impacts of IFN signaling on COVID19 pathology are multiple, with protective and harmful effects being documented. We report here a multi-omics investigation of IFN signaling in hospitalized COVID19 patients, defining the biosignatures associated with varying levels of 12 different IFN ligands. Previously we showed that seroconversion associates with decreased production of select IFN ligands (Galbraith et al, 2021). We show now that the antiviral transcriptional response in circulating immune cells is strongly associated with a specific subset of ligands, most prominently IFNA2 and IFNG. In contrast, proteomics signatures indicative of endothelial damage associate with levels of IFNB and IFNA6. Differential IFN ligand production is linked to distinct constellations of circulating immune cells. Lastly, IFN ligands associate differentially with activation of the kynurenine pathway, dysregulated fatty acid metabolism, and altered central carbon metabolism. Altogether, these results reveal specialized IFN ligand action in COVID19, with potential diagnostic and therapeutic implications.IMPACT STATEMENT Analysis of multi-omics signatures associated with 12 different IFN ligands reveals their specialized action in COVID19.Competing Interest StatementJME serves in the COVID Development Advisory Board for Elly Lilly and has provided consulting services to Gilead Sciences Inc.Funding StatementThis work was supported by National Institutes of Health grants R01AI150305 (JME), 3R01AI150305-01S1 (JME), R01AI145988 (KDS), UL1TR002535 (TDB), 3UL1TR002535-03S2 (TDB), R01HL146442 (AD), R01HL149714 (AD), R01HL148151 (AD), R21HL150032 (AD), P30CA046934 (JME, KH, AD), R35GM124939 (AAM), RM1GM131968 (AD, KCH), and K23AR070897 (EWYH), as well as grants from the Boettcher Foundation (KDS, EWYH) and Fast Grants (JME). Additional support was received from Chancellor's Discovery Innovation Fund at the CU Anschutz Medical Campus, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation, the LGA Foundation, and Lyda Hill Philanthropies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research participants were recruited and consented for participation in the COVID Biobank of the University of Colorado Anschutz Medical Campus [Colorado Multiple Institutional Review Board (COMIRB) Protocol # 20-0685]. Data was generated from deidentified biospecimens and linked to demographics and clinical metadata procured through the Health Data Compass of the University of Colorado under COMIRB Protocol # 20-1700.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData used in this manuscript are available via the COVIDome Explorer online researcher portal (covidome.org). The RNAseq data have been deposited in NCBI Gene Expression Omnibus, with series accession number GSE167000. The SOMAscan® Proteomics, MSD Cytokine Profiles, and Sample Metadata files have been deposited in Mendeley under entry doi:10.17632/2mc6rrc5j3.2. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD022817. The mass cytometry data has been deposited in Flow Repository (flowrepository.org) with Repository ID FR-FCM-Z367. Raw metabolomics MS data files and annotated reports are available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website (supported by NIH grant U2C-DK119886), the Metabolomics Workbench (metabolomicsworkbench.org) under the Project ID PR001110. These data can be accessed directly via the Project DOI: 10.21228/M8739H. https://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Project&ProjectID=PR001110 https://flowrepository.org/id/RvFrSYioKeUdYHXdkTD9TQPAXt4PqdkB5eie82h11JgAGSCQIneLKpcKd81Nzgwq http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD022817 https://data.mendeley.com/datasets/2mc6rrc5j3/1 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167000